Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
This was an open-label, multicentre, single-arm phase 2 trial done at 18 hospitals in Spain. At 24 months, progression-free survival was 77% in patients with stage IIIA NSCLC. Neoadjuant nivolumab could be added to platinum-based chemotherapy.
